Xoma Spinout Readies NDA For Hypertension Combination Product
This article was originally published in The Pink Sheet Daily
Executive Summary
New company Symplmed takes over Xoma’s perindopril partnership with Servier, readying a combination product with amlodipine for U.S. approval in hypertension, while holding options on two other fixed-dose combinations including the ACE inhibitor.